Vertex Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vertex Pharmaceuticals (VRTX).

Price Target Range — 7 Quarters

Analyst Consensus — 27 Analysts

21Buy

5Hold

1Sell

Consensus RatingBuy# Analysts27Avg. Consensus PT$543Upside to Avg. PT+5.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 11, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$515→$560
Sep 2, 2026	Morgan Stanley	Terence Flynn	Reinstates	Overweight	$665
Aug 5, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$560→$565
Aug 5, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$615→$617
Aug 4, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$525→$550
Aug 4, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$590→$595
Aug 4, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Hold	$436→$442
Jul 13, 2026	UBS	Michael Yee	PT Raise	Buy	$545→$585
Jul 13, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$542→$560
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$543→$570
Jul 7, 2026	Baird	Brian Skorney	PT Raise	Underperform	$330→$350
May 6, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$607→$615
May 5, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Hold	$437→$436
May 5, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$612→$616
May 5, 2026	Bernstein	William Pickering	PT Cut	Outperform	$577→$572
May 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$541→$543
Apr 30, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Hold	$441→$437
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$596→$612
Mar 18, 2026	Maxim Group	Naz Rahman	Upgrade	Hold→Buy	$575
Mar 11, 2026	Truist Securities	Joon Lee	PT Raise	Buy	$490→$525

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.

Benzinga Newsdesk

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.

Benzinga Newsdesk

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

PRO
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

PRO
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

People Also Watch

People Also Watch

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PROLive On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PROCNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PROTruist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

PROBarclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

PROTD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

People Also Watch

People Also Watch

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

PRO
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

PRO
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550